secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K/A
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001104659-24-031470
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec pre-announces Q4 2023 net revenue ~$9.2-9.7M, up 41-49% QoQ
------------------------------------------------------------------

- Q4 2023 net revenue expected $9.2-9.7M, a 41-49% increase vs Q3 2023.
- Full-year 2023 net revenue expected ~$20.7-21.2M.
- Audited full-year results expected on or about March 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/0001104659-24-031470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924031470/tm248156d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-031470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer